{"product_id":"recombinant-human-flt3-ligand-protein-bhp22200010","title":"Recombinant Human FLT3 Ligand Protein","description":"\u003cdiv class=\"bhp-desc\"\u003e\n\u003cstyle\u003e.bhp-desc{font-size:16px;color:#1a1a1a;line-height:1.7}.bhp-desc h2{font-size:18px;font-weight:700;color:#003366;margin:24px 0 10px;padding-bottom:6px;border-bottom:2px solid #003366}.bhp-desc p{margin:0 0 12px}.bhp-desc .bhp-spec-table{width:100%;border-collapse:collapse;margin:12px 0 18px}.bhp-desc .bhp-spec-table th{width:36%;text-align:left;padding:8px 12px;background:#e8f0fb;color:#003366;font-weight:600;vertical-align:top;border:1px solid #ccd9f0}.bhp-desc .bhp-spec-table td{padding:8px 12px;vertical-align:top;border:1px solid #ccd9f0}.bhp-desc .bhp-qc-badge{display:inline-block;background:#e6f4ea;color:#1a7a3c;border:1px solid #a8d5b5;border-radius:4px;padding:6px 14px;font-size:14px;font-weight:600}.bhp-desc .bhp-warning-box{background:#fff8e6;border-left:4px solid #e6a817;padding:10px 14px;margin:10px 0 14px;border-radius:0 4px 4px 0}.bhp-desc .bhp-app-wrap{overflow-x:auto}.bhp-desc .bhp-app-table{width:100%;border-collapse:collapse;margin:12px 0 18px;font-size:14px}.bhp-desc .bhp-app-table th{background:#e8f0fb;color:#003366;text-align:left;padding:8px 10px;border:1px solid #ccd9f0;vertical-align:top}.bhp-desc .bhp-app-table td{padding:8px 10px;border:1px solid #ccd9f0;vertical-align:top}.bhp-desc .bhp-cat-pill{display:inline-block;background:#003366;color:#fff;border-radius:20px;padding:3px 12px;font-size:13px;margin-bottom:10px}\u003c\/style\u003e\n\u003cspan class=\"bhp-cat-pill\"\u003eRecombinant Protein · Cytokine\u003c\/span\u003e\u003ch2\u003eProduct Overview\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eRecombinant Human FLT3 Ligand Protein\u003c\/strong\u003e (FLT3L) is a hematopoietic cytokine expressed in \u003cstrong\u003ehuman cells\u003c\/strong\u003e and supplied as a glycosylated monomer. It is tag-free, animal-free and xeno-free, and is lyophilized from a 0.2 µm-filtered PBS solution without carrier protein, with purity \u0026gt;95% by SDS-PAGE and endotoxin \u0026lt;0.5 EU\/µg.\u003c\/p\u003e\n\u003cp\u003eFLT3 Ligand is used in hematopoietic stem\/progenitor-cell culture, usually together with SCF and TPO, in dendritic-cell development and in staged differentiation of immune cells from pluripotent stem cells, as well as in FLT3\/CD135 signaling studies. Expression in human cells supports mammalian folding and glycosylation, and five peer-reviewed studies identify this FLT3 Ligand or its catalog number.\u003c\/p\u003e\n\u003cp\u003e\u003cspan class=\"bhp-qc-badge\"\u003eExpression system: Human cells · Tag-free · Animal-free\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2\u003eScientific Background\u003c\/h2\u003e\n\u003cp\u003eFLT3 Ligand is a glycoprotein cytokine produced by several stromal and immune-cell populations. The soluble form is released from a membrane-associated precursor and binds the receptor tyrosine kinase FLT3\/CD135 on early hematopoietic progenitors.\u003c\/p\u003e\n\u003cp\u003eReceptor activation engages PI3K–AKT, RAS–MAPK and STAT signaling, and the result depends on progenitor state and companion cytokines. FLT3L acts most clearly on early progenitors and dendritic-cell lineages, and is studied with SCF and TPO in HSPC culture and with stage-specific signals in dendritic, lymphoid and other immune-cell differentiation.\u003c\/p\u003e\n\u003ch2\u003eResearch Applications\u003c\/h2\u003e\n\u003cp\u003eFLT3 Ligand is mostly used in combination with other cytokines to support FLT3-positive early progenitors and dendritic-cell lineages. The table shows typical placements; it is a planning guide, not a universal protocol.\u003c\/p\u003e\n\u003cdiv class=\"bhp-app-wrap\"\u003e\u003ctable class=\"bhp-app-table\"\u003e\n\u003ctr\u003e\n\u003cth\u003eApplication\u003c\/th\u003e\n\u003cth\u003eRole of FLT3 Ligand\u003c\/th\u003e\n\u003cth\u003eCompanion context\u003c\/th\u003e\n\u003cth\u003eSuggested readouts\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCord-blood or adult CD34+ HSPC culture\u003c\/td\u003e\n\u003ctd\u003eSurvival and expansion of early progenitors\u003c\/td\u003e\n\u003ctd\u003eSCF and TPO, plus protocol-dependent signals\u003c\/td\u003e\n\u003ctd\u003eCell count, viability, CD34\/CD38\/CD90, CFU and engraftment assays\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ehPSC hematopoietic differentiation\u003c\/td\u003e\n\u003ctd\u003eSupport after hemogenic\/endothelial stages\u003c\/td\u003e\n\u003ctd\u003eSCF, TPO, IL-3, IL-7 and\/or Notch context\u003c\/td\u003e\n\u003ctd\u003eCD43, CD45, CD34, lineage markers and functional assays\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDendritic-cell research\u003c\/td\u003e\n\u003ctd\u003eExpansion of FLT3-responsive progenitors\u003c\/td\u003e\n\u003ctd\u003eLineage-specific maturation signals\u003c\/td\u003e\n\u003ctd\u003eDC subset markers, antigen presentation and cytokine output\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFLT3 signaling assay\u003c\/td\u003e\n\u003ctd\u003eReceptor stimulation\u003c\/td\u003e\n\u003ctd\u003eDefined serum-reduced or basal system\u003c\/td\u003e\n\u003ctd\u003ePhospho-FLT3, ERK, AKT, STAT5 and proliferation\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\u003c\/div\u003e\n\u003cp\u003e\u003cstrong\u003ePlanning considerations\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eDefine the developmental or immune-cell stage and confirm that the target population expresses FLT3\/CD135 or depends on the pathway.\u003c\/li\u003e\n\u003cli\u003eTake the starting dose from published or in-house qualified work and titrate it for each cell source, basal medium and readout; no universal working concentration or EC50 applies across systems.\u003c\/li\u003e\n\u003cli\u003eControl timing and companion cytokines, since signal order, duration and pathway interactions shape the outcome.\u003c\/li\u003e\n\u003cli\u003eInclude no-factor, vehicle and pathway-response controls, and assess identity, viability, signaling and function rather than cell number alone.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eProtein Specifications\u003c\/h2\u003e\n\u003ctable class=\"bhp-spec-table\"\u003e\n\u003ctr\u003e\n\u003cth\u003eTarget\u003c\/th\u003e\n\u003ctd\u003eFLT3 Ligand\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eAlternative names\u003c\/th\u003e\n\u003ctd\u003eFLT3L; Flt3 Ligand; FLT3-Ligand\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eSpecies\u003c\/th\u003e\n\u003ctd\u003eHuman\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eExpression system\u003c\/th\u003e\n\u003ctd\u003eHuman cells\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eStructure\u003c\/th\u003e\n\u003ctd\u003eGlycosylated monomer\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eProtein family\u003c\/th\u003e\n\u003ctd\u003eHematopoietic cytokine\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eTag\u003c\/th\u003e\n\u003ctd\u003eTag-free\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eAnimal origin\u003c\/th\u003e\n\u003ctd\u003eAnimal-free \/ Xeno-free\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eMolecular weight\u003c\/th\u003e\n\u003ctd\u003e24–30 kDa. Refer to the lot-specific Certificate of Analysis (CoA) for lot data.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003ePurity\u003c\/th\u003e\n\u003ctd\u003e\u0026gt;95% by SDS-PAGE\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eEndotoxin level\u003c\/th\u003e\n\u003ctd\u003e\u0026lt;0.5 EU\/µg\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eFormulation\u003c\/th\u003e\n\u003ctd\u003eLyophilized from a 0.2 µm-filtered solution in PBS without carrier protein\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eForm\u003c\/th\u003e\n\u003ctd\u003eLyophilized\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eBiological activity\u003c\/th\u003e\n\u003ctd\u003eProliferation of human OCI-AML5 cells\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eApplications\u003c\/th\u003e\n\u003ctd\u003eStem Cell Differentiation, Immunotherapy, Hematopoietic Differentiation, Cell Proliferation, Colony-Forming Unit Assay, Cell Signaling Studies\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\u003ch2\u003eBiological Activity \u0026amp; Quality Control\u003c\/h2\u003e\n\u003cp\u003eBiological activity is shown by dose-dependent stimulation of proliferation in human OCI-AML5 cells.\u003c\/p\u003e\n\u003cp\u003eLot-specific activity and purity data are provided on the Certificate of Analysis (CoA), available from BioHippo on request.\u003c\/p\u003e\n\u003ch2\u003eReconstitution\u003c\/h2\u003e\n\u003col\u003e\n\u003cli\u003eBriefly centrifuge the vial before opening.\u003c\/li\u003e\n\u003cli\u003eReconstitute in sterile PBS containing 0.1% endotoxin-free recombinant human serum albumin.\u003c\/li\u003e\n\u003cli\u003eMix gently and prepare single-use aliquots under sterile conditions.\u003c\/li\u003e\n\u003cli\u003eAvoid repeated freeze–thaw cycles.\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003ch2\u003eStorage \u0026amp; Shipping\u003c\/h2\u003e\n\u003ctable class=\"bhp-spec-table\"\u003e\n\u003ctr\u003e\n\u003cth\u003eStorage\u003c\/th\u003e\n\u003ctd\u003eAs supplied: −20°C to −80°C for up to 12 months from receipt. After reconstitution: 2°C to 8°C for up to 1 month, or −20°C to −80°C for up to 3 months, under sterile conditions. Avoid repeated freeze–thaw cycles.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eShipping\u003c\/th\u003e\n\u003ctd\u003ePlease contact us to confirm shipping conditions for this product.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\u003ch2\u003eSelected References\u003c\/h2\u003e\n\u003col\u003e\n\u003cli\u003eHannum C, Culpepper J, Campbell D, et al. (1994) Ligand for FLT3\/FLK2 receptor tyrosine kinase regulates growth of haematopoietic stem cells and is encoded by variant RNAs. Nature 368:643-648. \u003ca href=\"https:\/\/doi.org\/10.1038\/368643a0\" target=\"_blank\" rel=\"noopener\"\u003e10.1038\/368643a0\u003c\/a\u003e\n\u003c\/li\u003e\n\u003cli\u003eSavvides SN, Boone T, Andrew Karplus P (2000) Flt3 ligand structure and unexpected commonalities of helical bundles and cystine knots. Nat Struct Biol 7:486-491. \u003ca href=\"https:\/\/doi.org\/10.1038\/75896\" target=\"_blank\" rel=\"noopener\"\u003e10.1038\/75896\u003c\/a\u003e\n\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003ch2\u003eSafety \u0026amp; Handling\u003c\/h2\u003e\n\u003cdiv class=\"bhp-warning-box\"\u003e\u003cp style=\"margin:0\"\u003eHandle as a laboratory reagent and consult the linked SDS before use. Avoid repeated freeze–thaw cycles of the reconstituted protein.\u003c\/p\u003e\u003c\/div\u003e\n\u003cp\u003e\u003cem\u003eFor research use only. Not for diagnostic or therapeutic use.\u003c\/em\u003e\u003c\/p\u003e\n\u003c\/div\u003e","brand":"StemImmune LLC","offers":[{"title":"10 ug","offer_id":67641419202925,"sku":"HHM-FT-0010","price":101.0,"currency_code":"USD","in_stock":true},{"title":"100 ug","offer_id":67641427034477,"sku":"HHM-FT-0100","price":808.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/FLT3ligand1-500x500.png?v=1791572762","url":"https:\/\/www.ebiohippo.com\/products\/recombinant-human-flt3-ligand-protein-bhp22200010","provider":"BioHippo","version":"1.0","type":"link"}